Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B.
Margolin K, et al. Among authors: weber j.
Clin Cancer Res. 2007 Jun 1;13(11):3312-9. doi: 10.1158/1078-0432.CCR-06-1341.
Clin Cancer Res. 2007.
PMID: 17545537
Clinical Trial.